Genprex (GNPX) Hits New 12-Month Low After Earnings Miss

Genprex Inc (NASDAQ:GNPX)’s share price reached a new 52-week low during trading on Tuesday following a weaker than expected earnings announcement. The company traded as low as $1.28 and last traded at $1.30, with a volume of 53657 shares trading hands. The stock had previously closed at $1.31.

The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02).

Separately, Maxim Group assumed coverage on shares of Genprex in a research note on Friday, September 14th. They set a “buy” rating and a $5.00 price target on the stock.

WARNING: This story was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at

Genprex Company Profile (NASDAQ:GNPX)

Genprex, Inc, a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome.

Featured Story: Stock Selection – What is cash flow?

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with's FREE daily email newsletter.

Leave a Reply